Immune-based therapies for cytomegalovirus infection

Immunotherapy

Volumn 2, Issue 1, 2010, Pages 117-130

  Razonable, Raymund R ^a  

^a MAYO CLINIC   (United States)

Author keywords

Adoptive therapy; Cytomegalovirus; Immune reconstitution; Immunoglobulin; Vaccine

Indexed keywords

CIDOFOVIR; CYTOMEGALOVIRUS ANTIBODY; CYTOMEGALOVIRUS VACCINE; FOMIVIRSEN; FOSCARNET; GANCICLOVIR; GLYCOPROTEIN B; IMMUNOGLOBULIN; VALGANCICLOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AIDS PATIENT; ANTIVIRAL THERAPY; BRONCHIOLITIS OBLITERANS; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG FORMULATION; DRUG INHIBITION; DRUG MECHANISM; FETUS; GRAFT RECIPIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; PASSIVE IMMUNIZATION; PATHOGENESIS; PRIORITY JOURNAL; RETINITIS; REVIEW; T LYMPHOCYTE; VACCINATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL TRIALS AS TOPIC; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS VACCINES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY;

EID: 77952653546     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.09.82     Document Type: Review

References (66)

1. Smith KO, Rasmussen L: Morphology of cytomegalovirus (salivary gland virus). J. Bacteriol. 85, 1319-1325 (1963).
2. Razonable RR: Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients. Am. J. Health Syst. Pharm. 62(8 Suppl. 1), S7-S13 (2005).
3. Almeida LN, Azevedo RS, Amaku M, Massad E: Cytomegalovirus seroepidemiology in an urban community of Sao Paulo, Brazil. Rev. Saude Publica 35(2), 124-129 (2001).
4. de Ory F, Ramirez R, Garcia Comas L, Leon P, Sagues MJ, Sanz JC: Is there a change in cytomegalovirus seroepidemiology in Spain? Eur. J Epidemiol. 19(1), 85-89 (2004).
5. Colugnati FA, Staras SA, Dollard SC, Cannon MJ: Incidence of cytomegalovirus infection among the general population and pregnant women in the United States. BMC Infect. Dis. 7, 71 (2007).
6. Compton T, Kurt-Jones EA, Boehme KW et al.: Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2. J. Virol. 77(8), 4588-4596 (2003).
7. Kijpittayarit S, Eid AJ, Brown RA, Paya CV, Razonable RR: Relationship between Toll-like receptor 2 polymorphism and cytomegalovirus disease after liver transplantation. Clin. Infect. Dis. 44(10), 1315-1320 (2007).
8. + T cells in patients presenting with late-onset CMV disease several years after transplantation. Transpl. Infect. Dis. 11(1), 20-27 (2009).
9. + T cells in healthy carriers are continuously driven to replicative exhaustion. J. Immunol. 175(12), 8218-8225 (2005).
10. - transplant recipients. Am. J. Transpl. 5(5), 1065-1070 (2005).
11. Escobar MR, Allison MJ, Dalton HP: Etiology and laboratory diagnosis of infectious mononucleosis: II. Cytomegalovirus (CMV) mononucleosis. VA Med. Mon. 97(3), 191-192 (1970).
12. Razonable RR, Emery VC: Management of CMV infection and disease in transplant patients. 27-29 February 2004. Herpes 11(3), 77-86 (2004).
13. Razonable RR, Paya CV: Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts. Expert Rev. Anti-infect. Ther. 2(1), 27-41 (2004).
14. Neuwirth J, Gutman I, Hofeldt AJ et al.: Cytomegalovirus retinitis in a young homosexual male with acquired immunodeficiency. Ophthalmology 89(7), 805-808 (1982).
15. Whitley RJ: Congenital cytomegalovirus infection: epidemiology and treatment. Adv. Exp. Med. Biol. 549, 155-160 (2004).
16. Razonable RR, Rivero A, Rodriguez A et al.: Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J. Infect. Dis. 184(11), 1461-1464 (2001).
17. Razonable RR: Cytomegalovirus infection after liver transplantation: current concepts and challenges. World J. Gastroenterol. 14(31), 4849-4860 (2008).
18. Arthurs SK, Eid AJ, Pedersen RA et al.: Delayed-onset primary cytomegalovirus disease after liver transplantation. Liver Transpl. 13(12), 1703-1709 (2007).
19. Arthurs SK, Eid AJ, Pedersen RA et al.: Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin. Infect. Dis. 46(6), 840-846 (2008).
20. Kijpittayarit-Arthurs S, Eid AJ, Kremers WK et al.: Clinical features and outcomes of delayed-onset primary cytomegalovirus disease in cardiac transplant recipients. J. Heart Lung Transpl. 26(10), 1019-1024 (2007).
21. Eid AJ, Bakri SJ, Kijpittayarit S, Razonable RR: Clinical features and outcomes of cytomegalovirus retinitis after transplantation. Transpl. Infect. Dis. 10(1), 13-18 (2008).
22. Kimberlin DW, Lin CY, Sanchez PJ et al.: Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J. Pediatr. 143(1), 16-25 (2003). ■ Describes the benefits of ganciclovir treatment of infants with congenital cytomegalovirus (CMV) infection.
23. Nassetta L, Kimberlin D, Whitley R: Treatment of congenital cytomegalovirus infection: implications for future therapeutic strategies. J. Antimtcrob. Chemother. 63(5), 862-867 (2009).
24. Whitley RJ, Cloud G, Gruber W et al.: Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a Phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J. Infect. Dis. 175(5), 1080-1086 (1997). ■ Describes the benefits of ganciclovir treatment of infants with congenital CMV infection.
25. Jabs DA, Griffiths PD: Fomivirsen for the treatment of cytomegalovirus retinitis. Am. J. Ophthalmol. 133(4), 552-556 (2002).
26. Whitley RJ, Jacobson MA, Friedberg DN et al.: Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. International AIDS Society - USA. Arch. Intern. Med. 158(9), 957-969 (1998). ■ Describes the strategy for the management of CMV retinitis and other CMV diseases in AIDS patients.
27. Martin DF, Dunn JP, Davis JL et al.: Use of the ganciclovir implant for the treatment of cytomegalovirus retinitis in the era of potent antiretroviral therapy: recommendations of the International AIDS Society - USA panel. Am. J. Ophthalmol. 127(3), 329-339 (1999).
28. Aberg J, Kaplan JE, Libman H et al.: Primary Care Guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV Medicine Association of the Infectious Disease Society of America. Clin. Infect. Dis. 49, 651-681 (2009).
29. Jouan M, Saves M, Tubiana K et al.: Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 15(1), 23-31 (2001).
30. Whitcup SM, Fortin E, Lindblad AS et al.: Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis. J. Am. Med. Assoc. 282(17), 1633-1637 (1999).
31. Asberg A, Humar A, Rollag H et al.: Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am. J. Transpl. 7(9), 2106-2113 (2007).
32. Asberg A, Humar A, Jardine AG et al.: Long-term outcomes of CM V disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am. J. Transpl. 9(5), 1205-1213 (2009).
33. Razonable RR, Paya CV: Infections and allograft rejection - intertwined complications of organ transplantation. Swiss Med. Wkly 135(39-40), 571-573 (2005).
34. Spector SA, McKinley GF, Lalezari JP et al.: Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group. N Engl. J. Med. 334(23), 1491-1497 (1996).
35. + cell counts and CMV viremia: results of ACTG protocol A5030. HIV Clin. Trials 10(3), 143-152 (2009). ■ Describes the reduction in CMV end-organ diseases in the era when highly active antiretroviral therapy is widely used for the treatment of HIV infection.
36. Gane E, Saliba F, Valdecasas GJ et al.: Randomized trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group (corrected). Lancet 350(9093), 1729-1733 (1997).
37. Lowance D, Neumayer HH, Legendre CM et al.: Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N. Engl. J. Med. 340(19), 1462-1470 (1999).
38. Paya C, Humar A, Dominguez E et al.: Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am. J. Transpl. 4(4), 611-620 (2004).
39. Chandler SH, Handsfield HH, McDougall JK: Isolation of multiple strains of cytomegalovirus from women attending a clinic for sexually transmitted disease. J. Infect. Dis. 155(4), 655-660 (1987).
40. Manuel O, Pang XL, Humar A, Kumar D, Doucette K, Preiksaitis JK: An assessment of donor-to-recipient transmission patterns of human cytomegalovirus by analysis of viral genomic variants. J. Infect. Dis. 199(11), 1621-1628 (2009).
41. Gonczol E, Plotkin S: Development of a cytomegalovirus vaccine: lessons from recent clinical trials. Exp. Opin. Biol. Ther. 1(3), 401-412 (2001).
42. Sachs GW, Simmons RL, Balfour HH Jr: Cytomegalovirus vaccine: persistence of humoral immunity following immunization of renal transplant candidates. Vaccine 2(3), 215-218 (1984).
43. Plotkin SA, Smiley ML, Friedman HM et al.: Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants. Lancet 1(8376), 528-530 (1984). ■ One of the earliest clinical trials that indicated the ability of CMV vaccine to reduce severe CMV disease, but its inability to completely prevent primary CMV infection.
44. Brayman KL, Dafoe DC, Smythe WR et al.: Prophylaxis of serious cytomegalovirus infection in renal transplant candidates using live human cytomegalovirus vaccine. Interim results of a randomized controlled trial. Arch. Surg. 123(12), 1502-1508 (1988).
45. Plotkin SA, Starr SE, Friedman HM et al.: Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial. Ann. Intern. Med. 114(7), 525-531 (1991).
46. Plotkin SA, Higgins R, KurtzJB et al.: Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation. 58(11), 1176-1178 (1994).
47. Heineman TC, Schleiss M, Bernstein DI et al.: A Phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines. J. Infect. Dis. 193(10), 1350-1360 (2006).
48. Pass RF, Zhang C, Evans A et al.: Vaccine prevention of maternal cytomegalovirus infection. N. Engl. J Med. 360(12), 1191-1199 (2009). ■ Most recent report of a CMV vaccine (glycoprotein B subunit vaccine with MF59 adjuvant) provides promise that an effective vaccine is possible. The vaccine was able to reduce infection, albeit not completely, in women of childbearing age at risk for CMV infection.
49. Sinzger C: Entry route of HCMV into endothelial cells. J. Clin. Virol. 41(3), 174-179 (2008).
50. Wang D, Yu QC, Schroer J, Murphy E, Shenk T: Human cytomegalovirus uses two distinct pathways to enter retinal pigmented epithelial cells. Proc. Natl Acad. Sci. USA 104(50), 20037-20042 (2007).
51. Snydman DR, Werner BG, Heinze-Lacey B et al.: Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N. Engl. J. Med. 317(17), 1049-1054 (1987).
52. Bonaros N, Mayer B, Schachner T, Laufer G, Kocher A: CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis. Clin. Transpl. 22(1), 89-97 (2008).
53. Hodson EM, Jones CA, Strippoli GF, Webster AC, Craig JC: Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst. Rev. 18(2) CD005129 (2007).
54. Zamora MR, Nicolls MR, Hodges TN et al.: Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am. J. Transpl. 4(10), 1635-1642 (2004).
55. Ruttmann E, Geltner C, Bucher B et al.: Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation. Transplantation 81(10), 1415-1420 (2006).
56. Solidoro P, Delsedime L, Bergallo M et al.: Combined prophylaxis decreases incidence of CMV-associated pneumonia after lung transplantation. Transpl. Proc. 41(4), 1347-1348 (2009).
57. Nigra G, Adler SP, La Torre R, Best AM: Passive immunization during pregnancy for congenital cytomegalovirus infection. N. Engl. J Med. 353(13), 1350-1362 (2005). ■ This nonrandomized trial reports on the potential benefits of immunoglobulin therapy to reduce the incidence of congenital CMV infection in pregnant women with primary CMV infection.
58. + T lympho-cytes and the risk of CMV viremia after allogeneic hematopoietic stem cell transplantation. Transpl. Infect. Dis. (2009) (In press).
59. Holtappels R, Bohm V, Podlech J, Reddehase MJ: CD8 T-cell-based immunotherapy of cytomegalovirus infection: 'proof of concept' provided by the murine model. Med. Microbiol. Immunol. 197(2), 125-134 (2008).
60. Cobbold M, Khan N, Pourgheysari B et al.: Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J. Exp. Med. 202(3), 379-386 (2005).
61. Micklethwaite KP, Clancy L, Sandher U et al.: Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation. Blood 112(10), 3974-3981 (2008).
62. Bao L, Dunham K, Stamer M, Mulieri KM, Lucas KG: Expansion of cytomegalovirus pp65 and IE-1-specific cytotoxic T lymphocytes for cytomegalovirus-specific immunotherapy following allogeneic stem cell transplantation. Biol. Blood Marrow Transpl. 14(10), 1156-1162 (2008).
63. Li Pira G, Ivaldi F, Tripodi G, Martinengo M, Manca F: Positive selection and expansion of cytomegalovirus-specific CD4 and CD8 T cells in sealed systems: potential applications for adoptive cellular immunoreconstitution. J. Immunother. 31(8), 762-770 (2008).
64. Brestrich G, Zwinger S, Fischer A et al.: Adoptive T-cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy. Am. J. Transpl. 9(7), 1679-1684 (2009).
65. Weinberg A, Tierney C, Kendall MA et al.: Cytomegalovirus-specific immunity and protection against viremia and disease in HIV-infected patients in the era of highly active antiretroviras therapy. J. Infect. Dis. 193(4), 488-493 (2006).
66. List of vaccine identifiers. www.dinicaltrials.gov